Spero Therapeutics Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Spero Therapeutics Inc Unternehmen

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.

Spero Therapeutics Inc Informationen



BörsenkürzelSPRO

Name des UnternehmensSpero Therapeutics Inc

IPO-datumNov 02, 2017

CEORajavelu (Esther)

Anzahl der mitarbeiter32

WertpapierartOrdinary Share

GeschäftsjahresendeNov 02

Addresse675 Massachusetts Ave Ste 14

StadtCAMBRIDGE

BörseNASDAQ OMX - NASDAQ BASIC

LandUnited States of America

Postleitzahl02139-3309

Telefon18572421600

Websitehttps://sperotherapeutics.com/

BörsenkürzelSPRO

IPO-datumNov 02, 2017

CEORajavelu (Esther)

Führungskräfte von Spero Therapeutics Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Ankit Mahadevia, M.D.

Non-Executive Director

364.22K

-6572.00%

Ms. Esther Rajavelu

President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer

188.41K

-40270.00%

Mr. Timothy (Tim) Keutzer

Chief Operating Officer

145.31K

-1695.00%

Dr. Milind S. Deshpande, Ph.D.

Independent Director

91.45K

+20000.00%

Mr. Frank E. Thomas, CPA

Independent Chairman of the Board

75.00K

+20000.00%

Ms. Cynthia Smith

Independent Director

75.00K

+20000.00%

Ms. Kathleen Tregoning

Independent Director

75.00K

+20000.00%

Dr. Patrick Volkert Jozef Johannes Vink, M.D.

Lead Independent Director

--

Dr. John C. Pottage, Jr., M.D.

Independent Director

--

Mr. Scott T. Jackson

Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Ankit Mahadevia, M.D.

Non-Executive Director

364.22K

-6572.00%

Ms. Esther Rajavelu

President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer

188.41K

-40270.00%

Mr. Timothy (Tim) Keutzer

Chief Operating Officer

145.31K

-1695.00%

Dr. Milind S. Deshpande, Ph.D.

Independent Director

91.45K

+20000.00%

Mr. Frank E. Thomas, CPA

Independent Chairman of the Board

75.00K

+20000.00%

Ms. Cynthia Smith

Independent Director

75.00K

+20000.00%

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Collaboration Revenue Related Party

3.05M

56.01%

Grant Revenue

2.39M

43.99%

Collaboration Revenue

0.00

0.00%

Nach RegionUSD

Name

Umsatz

Anteil

United States

5.44M

100.00%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Collaboration Revenue Related Party

3.05M

56.01%

Grant Revenue

2.39M

43.99%

Collaboration Revenue

0.00

0.00%

Aktionärsstatistik

Aktualisiert: Sat, Feb 7

Aktionäre

Aktionärstypen

Aktionäre

Anteil

GSK plc

16.31%

Pfizer Inc

4.19%

The Vanguard Group, Inc.

3.70%

Anson Funds Management LP.

2.85%

Renaissance Technologies LLC

2.58%

Andere

70.37%

Aktionäre

Anteil

GSK plc

16.31%

Pfizer Inc

4.19%

The Vanguard Group, Inc.

3.70%

Anson Funds Management LP.

2.85%

Renaissance Technologies LLC

2.58%

Andere

70.37%

Aktionärstypen

Aktionäre

Anteil

Corporation

20.51%

Hedge Fund

6.27%

Investment Advisor

5.88%

Individual Investor

2.87%

Investment Advisor/Hedge Fund

2.52%

Venture Capital

1.64%

Research Firm

0.20%

Bank and Trust

0.02%

Andere

60.09%

Institutionelle Beteiligung



Aktualisiert: Thu, Jan 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

108

9.24M

16.40%

-3.05M

2025Q3

106

9.05M

16.08%

-5.89M

2025Q2

114

26.06M

46.61%

-2.84M

2025Q1

116

27.38M

49.07%

-1.56M

2024Q4

125

27.51M

50.50%

+2.91M

2024Q3

143

24.19M

44.62%

-8.19M

2024Q2

160

25.74M

47.53%

-7.31M

2024Q1

203

25.36M

47.08%

-8.60M

2023Q4

209

24.88M

47.35%

-1.62M

2023Q3

223

24.62M

47.01%

-2.06M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

GSK plc

9.19M

16.31%

--

Mar 27, 2025

Pfizer Inc

2.36M

4.19%

--

Sep 30, 2025

The Vanguard Group, Inc.

1.99M

3.53%

+39.47K

+2.02%

Sep 30, 2025

Anson Funds Management LP.

1.60M

2.85%

-11.90K

-0.74%

Sep 30, 2025

Renaissance Technologies LLC

1.45M

2.58%

+620.60K

+74.58%

Sep 30, 2025

Alphabet, Inc.

889.98K

1.58%

--

Sep 30, 2025

Geode Capital Management, L.L.C.

527.48K

0.94%

+16.78K

+3.29%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

433.55K

0.77%

--

Sep 30, 2025

Rajavelu (Esther)

188.41K

0.33%

-40.27K

-17.61%

Nov 07, 2025

Mahadevia (Ankit)

364.22K

0.65%

-6.57K

-1.77%

Aug 28, 2025

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

Invesco NASDAQ Future Gen 200 ETF

0.63%

Avantis US Small Cap Equity ETF

0%

iShares Micro-Cap ETF

0%

Invesco NASDAQ Future Gen 200 ETF

Anteil0.63%

Avantis US Small Cap Equity ETF

Anteil0%

iShares Micro-Cap ETF

Anteil0%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten